Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of chiauranib plus nab-paclitaxel and gemcitabine as first-line treatment for locally advanced or metastatic pancreatic ductal adenocarcinoma
CTR20242363Phase 2Active
- Sponsor
- Chipscreen Biosciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of chiauranib in pancreatic adenocarcinoma (PDAC), sponsored by Chipscreen Biosciences. Started Aug 2024; status: active.
02
Drugs
chiauranib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20242363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242363.